• Explore /
  • Poster
  • / NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high risk head and neck squamous cell carcinoma (HNSCC).

NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high risk head and neck squamous cell carcinoma (HNSCC).

Abstract Poster

Authors

Julie Bauman

Julie E. Bauman

University of Arizona Cancer Center, Tucson, AZ

Julie E. Bauman , Jonathan Harris , Ravindra Uppaluri , Min Yao , Robert L. Ferris , Josephine Chen , Richard C. Jordan , Nikhil Purushottam Joshi , Srinivas Jujjuvaparu , Dukagjin Blakaj , Mohammad Razaq , Jawad Sheqwara , Loren K. Mell , Neilayan Sen , David Anthony Clump , Madhur Garg , Emrullah Yilmaz , Quynh-Thu Le

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Local-Regional Disease

Clinical Trial Registration Number

NCT02775812

Citation

J Clin Oncol 37, 2019 (suppl; abstr 6023)

DOI

10.1200/JCO.2019.37.15_suppl.6023

Abstract #

6023

Poster Bd #

12

Abstract Disclosures

Similar Posters

First Author: Sidharth Puram

First Author: Philippe L. Bedard

First Author: Christophe Le Tourneau

First Author: Christophe Le Tourneau